Ulifosep 100000Iu Inj

Ulifosep 100000Iu Inj belongs to the class of medicine called protease inhibitors. It is used in the treatment of severe sepsis (a condition triggered by an extreme response of the immune system to infections) and acute pancreatitis (inflammation of the pancreas).

Ulifosep 100000Iu Inj contains Ulinastatin as an active ingredient, which belongs to the protease inhibitor class of drugs. It works by inhibiting serine proteases, including trypsin, chymotrypsin, kallikrein, plasmin, thrombin, factors IXa, Xa, XIa, and XlIa. This helps prevent organ dysfunction.

Ulifosep 100000Iu Inj may cause certain side effects, such as nausea, vomiting, headache, skin rash, itching, diarrhoea, allergic reactions and pain at the site of injection. These side effects do not require medical attention and gradually resolve over time. A trained healthcare professional will administer it. Do not self-administer.

Ulifosep 100000Iu Inj should be avoided if you are allergic to it or any other components present in it. Before administration, inform your doctor if you have liver/kidney disease, cardiac disorders, bleeding disorders or respiratory conditions. It is unknown whether Ulifosep 100000Iu Inj is suitable for use in pregnant and breastfeeding mothers. Hence, inform your doctor if you are pregnant, are planning to become pregnant or are breastfeeding beforehand.

Ulifosep 100000Iu Inj is used in the treatment of Severe Sepsis and Acute Pancreatitis. The detailed uses of Ulifosep 100000Iu Inj are as follows:

• Acute and chronic pancreatitis: Ulifosep 100000Iu Inj helps reduce inflammation in the pancreas by inhibiting digestive enzymes and inflammatory mediators. It is commonly used in both acute flare-ups and chronic cases to prevent further tissue damage.
• Severe sepsis and septic shock: Ulifosep 100000Iu Inj is used as part of supportive therapy in sepsis, where it helps control the body’s overwhelming inflammatory response to infection. This can improve survival rates and reduce organ damage.
• Post-surgical inflammation and trauma: Ulifosep 100000Iu Inj may be administered after major surgeries or traumatic injuries to minimize systemic inflammation and support recovery.

• Follow your doctor’s instructions on the dosage and timing of this medication to ensure safety and optimal results.
• Ulifosep 100000Iu Inj is administered by a trained healthcare professional.
• Do not self-administer.

Ulifosep 100000Iu Inj contains Ulinastatin as an active ingredient used in the treatment of sepsis and pancreatitis. It belongs to the protease inhibitor class of drugs that works by activating and inhibiting serine proteases, including trypsin, chymotrypsin, kallikrein, plasmin, granulocyte elastase, cathepsin, thrombin, and factors IXa, Xa, XIa, and XlIa. This reduces the pro-inflammatory response due to disease and helps prevent organ dysfunction.

Ulifosep 100000Iu Inj should be avoided if you are allergic to it or any other components present in it. Let your doctor know about your complete medical history, including current medication, to rule out any side effects/interactions. Before administration, inform your doctor if you have liver/kidney disease, cardiac disorders, bleeding disorders or respiratory conditions. Ulifosep 100000Iu Inj should be avoided in children as safety and efficacy are not established. It is unknown whether Ulifosep 100000Iu Inj is suitable for use in pregnant and breastfeeding mothers. Hence, inform your doctor if you are pregnant, are planning to become pregnant or are breastfeeding beforehand.